Skip to main content
Premium Trial:

Request an Annual Quote

Assurex Pharmacogenomics Tests to Use Luminex xTag Technology

NEW YORK (GenomeWeb) – Luminex today announced that its xTAG universal tag technology has been selected for use in Assurex Health's GeneSight neuropsychiatric pharmacogenomics tests.

Gene Sight compares patients' DNA signatures with known pharmacology in order to predict how they might react to medicines used to treat depression, post-traumatic stress disorder, anxiety, bipolar disease, schizophrenia, and other behavioral health conditions.

According to Luminex, its technology will enhance the processing speed and capacity of the Gene Sight tests. "In addition, the flexibility of the Luminex platform will allow us to add new biomarkers as our needs continue to expand," Assurex COO Donald Wright said in a statement.

Specific terms of the arrangement were not disclosed.